Floatz logo

Adoptive Therapy With Autologous Mc2 Tcr T Cells

Melanoma, Uveal

Erasmus Medical CenterCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

63 Active assets in the Melanoma, Uveal cohort.

Asset / SponsorPhaseRating
Ifa
Craig L Slingluff, Jr
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BB
Sargramostim
Thomas Jefferson University
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2/3BB
Darovasertib
IDEAYA Biosciences
Phase 3BB

View all 50 →

Same molecule, other indications

Adoptive Therapy With Autologous Mc2 Tcr T Cells is also rated in:

head and neck cancerDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →